Evaluation of MCAM expression in correlation with clinicopathological parameters of gastric cancer.

Publication date: Jul 04, 2025

MCAM (Melanoma Cell Adhesion Molecule) is an adhesion protein belonging to the immunoglobulin superfamily, which was identified as a melanoma-specific protein. It is now clear that it can also be found in other types of neoplasms, e. g. in the carcinoma of the prostate, breast, ovary and stomach. MCAM plays a major pro-migratory role in the vascular system, promoting metastases. Therefore the study objective was to immunohistochemically evaluate MCAM expression in gastric cancer as well as to examine the correlation with chosen clinical-histopathological parameters. The study has shown that positive expression of MCAM was observed in cancer cells in 42. 5% and in stromal cells in 33. 3% of patients. The expression was more frequently seen in low desmoplasia tumors. The positive expression was also associated with higher grade of Helicobacter pylori infection. No correlation was noted with the overall survival rate. The expression of MCAM in stroma showed no correlation with clinical-histopathological parameters and patients’ survival. The assessment of MCAM expression is not a useful marker to identify tumor stage nor it is a prognostic factor of gastric cancer. However, this protein may contribute to the process of desmoplastic stroma formation and be involved in the mechanism of inflammatory reaction.

Open Access PDF

Concepts Keywords
Cancer Adhesive proteins
Clear Adult
Clinicopathological Aged
Prostate Aged, 80 and over
Proteins Biomarkers, Tumor
Biomarkers, Tumor
CD146 Antigen
CD146 Antigen
Desmoplasia
Epithelial-mesenchymal transition
Female
Gastric cancer
Helicobacter Infections
Helicobacter pylori
Helicobacter pylori
Humans
Immunohistochemistry
Male
MCAM
MCAM protein, human
Middle Aged
Neoplasm Staging
Prognosis
Stomach Neoplasms
Stromal Cells

Semantics

Type Source Name
disease MESH gastric cancer
pathway KEGG Gastric cancer
disease MESH melanoma
pathway KEGG Melanoma
disease MESH neoplasms
disease MESH carcinoma
disease MESH metastases
disease MESH infection
disease MESH death
pathway REACTOME Immune System
disease MESH inflammation
drug DRUGBANK Coenzyme M
pathway REACTOME Apoptosis
disease MESH Lymph node metastasis
disease MESH pathological processes
disease MESH residual tumor
disease MESH urinary bladder cancer
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH recurrence
disease MESH pathogenesis
disease MESH Helicobacter Infections

Original Article

(Visited 18 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *